Eye Patient Adherence and Compliance Study

This study will enroll adult patients with glaucoma who are identified as being at high risk for poor medication adherence or inconsistent follow-up with clinic visits. Following informed consent, participants will undergo baseline assessments that include a structured questionnaire to identify barriers to adherence and compliance, as well as standardized tools to measure medication adherence and vision-related quality of life. Clinical information relevant to glaucoma management will be obtained as part of routine care.

Each participant will then be assigned to a single, tailored intervention based on their most significant self-identified barrier to care. These interventions reflect established components of standard glaucoma care and may include targeted education about the disease and its treatment, reminder systems to support medication use, training or assistance with proper eye drop administration, coordination of transportation for clinic visits, or enhanced care navigation and referral support. The goal is to provide individualized, practical support that directly addresses the participant's primary challenge.

All participants will continue to receive their usual ophthalmic care throughout the study period, and no experimental therapies will be introduced. Follow-up assessments will be conducted at multiple time points over approximately 12 months to evaluate changes in medication adherence, clinic attendance, and quality of life. These assessments will use the same validated tools administered at baseline to allow for comparison over time.

Data collected during the study will be analyzed to assess within-participant changes in outcomes following the intervention. The study will also explore patterns between types of barriers and improvements in adherence and related outcomes. The findings are intended to inform future approaches to improving glaucoma care by identifying practical, patient-centred strategies that can be integrated into routine clinical practice.

Participants will be eligible for inclusion if they meet all of the following criteria:

• Adults aged 18 years and older
• Clinical diagnosis of glaucoma or ocular hypertension confirmed by an ophthalmologist
• Currently prescribed at least one topical intraocular pressure (IOP)-lowering medication
• Identified as high risk for non-adherence and/or poor follow-up, defined by one or more of the following:
• Self-reported or documented missed ≥20% of prescribed eye drops
• Missed two or more glaucoma clinic appointments
• Evidence of structural or functional glaucoma progression (e.g., OCT or visual field deterioration)
• Willing to participate in study interventions and follow-up assessments Able to communicate in the study language.

Exclusion criteria

Participants will be excluded if they meet any of the following criteria:

• Significant cognitive impairment, neurodegenerative disease, or severe psychiatric illness limiting participation or understanding of the intervention
• Participation in another interventional study targeting glaucoma adherence or follow-up
• Anticipated inability to complete 12-month follow-up (e.g., planned relocation or transfer of care outside the study catchment area)